| S. No. |
Type of Media |
Column |
Mobile Phase |
Detector |
Chromatographic conditions |
Reference |
| 1. |
Human serum |
YMC ODS (23 × 4.0 mm)
YMC ODS (150 × 4.6 mm) |
Phase A: Acetonitrile and potassium dihydrogen phosphate (20 mM) in ratio of 60:40, pH 4.0
Phase B: Acetonitrile and dihydrogen phosphate (20 mM) in ratio of 60:40, pH 6.0 |
UV (229 nm) |
Flow rate: 1.0 mL.min-1 Temperature: 40°C |
[36] |
| 2. |
Human serum and urine |
Inertsil ODS-2 ( 150 × 4.6 mm, 5μm) |
First column: 0.02 M potassium dihydrogen phosphate Acetonitrile (40:60) adjusted to pH 4.0 with 85 orthophosphoric acid
Second column: 0.02 M potassium dihydrogen phosphate Acetonitrile (40:60) adjusted to pH 6.0 with 1M NaOH |
Fluorescence detector (Excitation and Emission wavelengths set at 270 and 390 nm) |
Flow rate: 1.0 mL.min-1 Temperature: 40°C |
[37] |
| 3. |
Human plasma and urine |
Spherisorb S3P (100 × 4.6 mm, 3 μm Hichrom) |
Candesartan (Plasma):
100 ml citrate buffer (pH 3.1, I=0.5 containing 50 mM TBA), 185 ml acetonitrile, 180 ml methanol and diluting to 1000 ml with water |
Fluorescence detector (Excitation and Emission wavelengths set at 265 and 395 nm) |
Flow rate: 0.9 mL.min-1 Temperature: room |
[40] |
Candesartan cilexetil (Plasma & urine):
200 ml phosphate buffer (pH 2.8, I=0.1 containing 12.5 mM TBA), 420 ml acetonitrile and diluting to 1000 ml with water |
Flow rate: 1.0 mL.min-1 Temperature: room |
Candesartan (Urine):
Phase A: 200 ml phosphate buffer (pH 2.8, I=0.1 containing 12.5 mM TBA), 200 ml acetonitrile and diluting to 1000 ml with water
Phase B: 200 ml phosphate buffer (pH 2.8, I=0.1 containing 12.5 mM TBA), 600 ml acetonitrile and diluting to 1000 ml with water |
Flow rate: 1.0 mL.min-1 Temperature: room |
| 4. |
Human plasma |
Novapak guard column (20 × 39 mm, 4 μm)
muBondapak (300 × 3.9 mm, 10 μm) |
Acetonitrile (5 mM) acetate buffer (pH 4) |
Fluorescence detector (Excitation and Emission wavelengths set at 250 and 375 nm) |
Flow rate: 1.0 to 1.2 mL.min-1 Temperature: room |
[41] |
| 5. |
Human plasma and urine |
Betasil (250mm × 4.6mm, 5μm) |
Acetonitrile and Sodium acetate buffer solution (5mM, pH 3.5) in the ratio of 40:60) |
PDA (250 nm) and fluorescence (Excitation and Emission wavelengths set at 250 and 380 nm) |
Flow rate: 1.0 mL.min-1 |
[42] |
| 6. |
In vitro dissolution |
Inertsil ODS-3 (250 × 4.6-mm, 5 μm) |
0.02 M monobasic potassium phosphate, acetonitrile, and triethylamine in the ratio of 40:60:0.2 (pH adjusted to 6.0 using phosphoric acid) |
UV (254 nm) |
Flow rate: 2.0 mL.min-1 Temperature: 25°C |
[43] |
| 7. |
Stability studies |
Hypersil ODS (250 × 4.6 mm, 5 μm) |
0.02M Potassium dihydrogen phosphate solution and acetonitrile (2:8), pH 4.0 was adjusted with 85 phosphoric acid |
UV (254 nm) |
Flow rate: 1.0 mL.min-1 Temperature: ambient |
[44] |
| 8. |
Drug analysis |
Zorbax SB-Phenyl |
0.1 mol.L-1 sodium acetate (pH 5.5), acetonitrile and methanol in 10:9:6 v/v/v ratio |
UV (230 nm) |
|
[45] |
| 9. |
Drug analysis |
Hypersil ODS (250 × 4.6 mm, 5 μm) |
Tetra butyl ammonium hydrogen sulphate 10 mM (pH 3.37): methanol (15:85) |
UV (270 nm) |
Flow rate: 1.0 mL.min-1 Temperature: ambient |
[46] |
| 10. |
Drug analysis |
Hypersil Phenyl 2 (250 × 4.6 mm, 5 μm) |
0.02 M potassium dihydrogen phosphate, methanol, and triethylamine (25:75:0.2 v/v), pH 6.0 ± 0.1 was adjusted by addition of 10 orthophosphoric acid |
UV (271 nm) |
Flow rate: 1.0 mL.min-1 Temperature: room |
[47] |
| 11. |
Everted gut sac (Rat) |
Shim-pack VP-ODS
(150 × 4.6 mm, 5 μm) |
Acetonitrile: Methanol: water: glacial acetic acid (40:35:25:0.1 v/v), pH 6.8 |
UV (255 nm) |
Flow rate: 1.0 mL.min-1 Temperature: ambient |
[48] |